Søgaard Mette, Farkas Dóra Körmendiné, Ehrenstein Vera, Jørgensen Jens Otto Lunde, Dekkers Olaf M, Sørensen Henrik Toft
Departments of Clinical EpidemiologyEndocrinology and Internal Medicine (MEA)Aarhus University Hospital, Olof Palmes Allé 43-45, DK-8200 Aarhus N, DenmarkDepartments of Endocrinology and Clinical EpidemiologyLeiden University Medical Center, Leiden, The Netherlands
Departments of Clinical EpidemiologyEndocrinology and Internal Medicine (MEA)Aarhus University Hospital, Olof Palmes Allé 43-45, DK-8200 Aarhus N, DenmarkDepartments of Endocrinology and Clinical EpidemiologyLeiden University Medical Center, Leiden, The Netherlands.
Eur J Endocrinol. 2016 Apr;174(4):409-14. doi: 10.1530/EJE-15-0989.
The association between thyroid disease and breast cancer risk remains unclear. We, therefore examined the association between hypothyroidism, hyperthyroidism and breast cancer risk.
This was a population-based cohort study.
Using nationwide registries, we identified all women in Denmark with a first-time hospital diagnosis of hypothyroidism or hyperthyroidism, 1978-2013. We estimated the excess risk of breast cancer among patients with hypothyroidism or hyperthyroidism compared with the expected risk in the general population, using standardized incidence ratios (SIRs) as a measure of risk ratio. Breast cancer diagnoses in the first 12 months following diagnosis of thyroid disease were excluded from the calculations to avoid diagnostic work-up bias.
We included 61, 873 women diagnosed with hypothyroidism and 80, 343 women diagnosed with hyperthyroidism. Median follow-up time was 4.9 years (interquartile range (IQR): 1.8-9.5 years) for hypothyroidism and 7.4 years (IQR: 3.1-13.5 years) for hyperthyroidism. Hyperthyroidism was associated with a slightly increased breast cancer risk compared with the general population (SIR: 1.11, 95% CI: 1.07-1.16), which persisted beyond 5 years of follow-up (SIR: 1.13, 95% CI: 1.08-1.19). In comparison, hypothyroidism was associated with a slightly lower risk of breast cancer (SIR: 0.94, 95% CI: 0.88-1.00). Stratification by cancer stage at diagnosis, estrogen receptor status, age, comorbidity, history of alcohol-related disease and clinical diagnoses of obesity produced little change in cancer risk.
We found an increased risk of breast cancer in women with hyperthyroidism and a slightly decreased risk in women with hypothyroidism indicating an association between thyroid function level and breast cancer risk.
甲状腺疾病与乳腺癌风险之间的关联仍不明确。因此,我们研究了甲状腺功能减退、甲状腺功能亢进与乳腺癌风险之间的关联。
这是一项基于人群的队列研究。
利用全国性登记处的数据,我们确定了1978年至2013年在丹麦首次因甲状腺功能减退或甲状腺功能亢进住院诊断的所有女性。我们使用标准化发病比(SIRs)作为风险比的衡量指标,估计甲状腺功能减退或甲状腺功能亢进患者患乳腺癌的额外风险与一般人群的预期风险相比。为避免诊断检查偏差,甲状腺疾病诊断后前12个月内的乳腺癌诊断被排除在计算之外。
我们纳入了61873名被诊断为甲状腺功能减退的女性和80343名被诊断为甲状腺功能亢进的女性。甲状腺功能减退患者的中位随访时间为4.9年(四分位间距(IQR):1.8 - 9.5年),甲状腺功能亢进患者为7.4年(IQR:3.1 - 13.5年)。与一般人群相比,甲状腺功能亢进与乳腺癌风险略有增加相关(SIR:1.11,95%CI:1.07 - 1.16),这种关联在随访5年后仍然存在(SIR:1.13,95%CI:1.08 - 1.19)。相比之下,甲状腺功能减退与乳腺癌风险略有降低相关(SIR:0.94,95%CI:0.88 - 1.00)。按诊断时的癌症分期、雌激素受体状态、年龄、合并症、酒精相关疾病史和肥胖临床诊断进行分层,癌症风险变化不大。
我们发现甲状腺功能亢进女性患乳腺癌的风险增加,甲状腺功能减退女性的风险略有降低,这表明甲状腺功能水平与乳腺癌风险之间存在关联。